Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2025-08-25 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes an explanatory note referencing a press release attached as Exhibit 99.1. The document is short (2108 characters) and primarily serves as a regulatory filing to disclose the press release. It does not contain detailed financial statements or substantive financial data, nor is it an annual or interim report. It is not a certification or officer attestation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-08-25 English
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Earnings Release Classification · 95% confidence The document is a press release from argenx announcing positive topline results from a Phase 3 clinical trial (ADAPT SERON study). It details the study's primary endpoint, future regulatory submission plans (sBLA), and provides safety information. It is a standard corporate announcement of clinical trial results, which falls under the category of a general regulatory announcement or press release for material company news. Q3 2025
2025-08-25 English
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Regulatory Filings Classification · 95% confidence The document is a short press release (under 3,000 characters) announcing an upcoming R&D webinar. It does not contain the actual presentation materials, financial results, or regulatory filings, but rather serves as an announcement of an event. Since it does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', and it is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements.
2025-08-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Regulatory Filings Classification · 95% confidence The document is a press release issued by argenx announcing a partnership with Monica Seles to raise awareness for Myasthenia Gravis. It does not contain financial results, board changes, or regulatory filings, but rather serves as a general corporate announcement regarding a marketing/awareness initiative. As it does not fit into the specific categories like ER, 10-K, or MANG, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-08-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.